Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selinexor with Carfilzomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma
NCT02199665Phase 1Completed
- Sponsor
- University of Chicago
- Start
- Jun 2014
- Primary completion
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of selinexor in multiple myeloma (MM), sponsored by University of Chicago. Primary endpoint: Maximum Tolerated Dose at 28 days. Started Jun 2014; status: completed.
02
Drugs
selinexor
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT02199665.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02199665.